Skip to Content

Join the 'Regranex' group to help and get support from people like you.

Regranex News

Hawaii Facing Rise in Dengue Fever Cases

Posted 3 Dec 2015 by Drugs.com

THURSDAY, Dec. 3, 2015 – Do your winter travel plans include Hawaii? You may want to pack bug repellent, experts say. That's because the Big Island of Hawaii is facing an outbreak of dengue fever – a mosquito-borne virus that can cause terrible headache and crushing pain in the muscles and joints. State health officials have confirmed 117 cases of dengue fever on the Big Island since mid-September, including 103 local residents and 14 visitors to the island. One other case has been reported on the island of Oahu, but health officials say it was not locally transmitted and is not tied to the new outbreak. The jump in cases has prompted top experts from the U.S. Centers for Disease Control and Prevention to visit the island this week to try and help, CNN reported Wednesday. "I don't think travelers should be overly worried, but they should take care to avoid mosquitoes as much as ... Read more

Related support groups: Therapeutic, Hypercare, Sulfur, Drysol, Rogaine, Psoriasin, Calamine, Vaniqa, Capsaicin, Zinc Oxide, Arnica, Protopic, Viral Infection, Elidel, Desitin, Calmoseptine, Capzasin, Selenium Sulfide, Coal Tar, Benzoin

Retail Prices of Dermatology Drugs Skyrocket

Posted 25 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 25, 2015 – Patients using prescription creams, gels, sprays and pills for skin conditions may shell out substantially more at the pharmacy than they did just six years ago, a new study suggests. Between 2009 and 2015, retail prices of brand-name dermatologic drugs rose 401 percent, on average, study authors reported Nov. 25 in JAMA Dermatology. Even generics have succumbed to price inflation, up 279 percent between 2011 and 2014, based on the drugs surveyed. Price increases for skin treatments far outpaced the general inflation rate of 11 percent during the six-year study period, the researchers said. "Cancer drugs were the worst in terms of the numbers" – up 1,240 percent or nearly $11,000 over the six-year study period – primarily because of two medicines, said Dr. Steven Rosenberg, voluntary professor of dermatology at the University of Miami Miller School of ... Read more

Related support groups: Monistat, RID, Monistat 3, Eczema, Voltaren Gel, Monistat 7, Dermatitis, Clobetasol, Contact Dermatitis, Bactroban, Mupirocin, Therapeutic, Maintain, Hypercare, Drysol, Sulfur, Retin-A, Efudex, Fluocinonide, Epiduo

FDA Medwatch Alert: Regranex (becaplermin) Gel

Posted 6 Jun 2008 by Drugs.com

[UPDATE 06/06/2008] FDA informed healthcare professionals that a Boxed Warning was added to prescribing information for Regranex that describes an increased risk of death from cancer in patients treated with three or more tubes of Regranex compared with those patients who did not use the product. FDA recommends that Regranex be used only when the benefits can be expected to outweigh the risks.[Posted 03/27/2008] The FDA is conducting a safety review based on study data suggesting there may be an increased risk of death from cancer in diabetic patients using Regranex (becaplermin) Gel, a skin product used to heal leg and foot ulcers. While the review is ongoing, the FDA recommends health care professionals discuss the potential risks and benefits of using Regranex with their patients.This communication is in keeping with FDA’s commitment to inform the public about its ongoing ... Read more

Related support groups: Regranex

FDA Medwatch Alert: Regranex (becaplermin) Gel

Posted 27 Mar 2008 by Drugs.com

[Posted 03/27/2008] The FDA is conducting a safety review based on study data suggesting there may be an increased risk of death from cancer in diabetic patients using Regranex (becaplermin) Gel, a skin product used to heal leg and foot ulcers. While the review is ongoing, the FDA recommends health care professionals discuss the potential risks and benefits of using Regranex with their patients. This communication is in keeping with FDA’s commitment to inform the public about its ongoing safety reviews of drugs. As soon as this review is complete, FDA will communicate the conclusions and recommendations to the public. [March 27, 2008 - Communication About an Ongoing Safety Review - FDA] Read more

Related support groups: Regranex

Ask a Question

Further Information

Regranex Patient Information at Drugs.com